SCHEMBL2069508

SCHEMBL2069508

COc1ccc(C2Cc3ccc(O)cc3OC2=O)cc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.59
KMT2A Q03164 3/20 0.56
POLB P06746 1/20 0.56
RECQL P46063 1/20 0.56
CYP1A1 P04798 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP1B1 Q16678 1/20 0.46
ALOX15 P16050 1/20 0.46
ALOX12 P18054 1/20 0.46
LMNA P02545 1/20 0.46
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
HPGD P15428 2/20 0.44
CYP19A1 P11511 1/20 0.44
THRB P10828 1/20 0.44
MAOB P27338 1/20 0.43
CBS P35520 1/20 0.43
KIT P10721 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2030055 0.88 ESR2 (0.51) ALDH1A1KMT2AALOX15ALOX12MEN1
SCHEMBL3357789 0.86 ALOX15 (0.57) ALDH1A1KMT2APOLBRECQLCYP1A1
SCHEMBL14389073 0.83 ALDH1A1 (0.52) ALDH1A1KMT2APOLBRECQLMEN1
SCHEMBL10685633 0.82 ALDH1A1 (0.55) ALDH1A1KMT2ACYP1A1CYP1A2CYP1B1
SCHEMBL28907445 0.82 ALDH1A1 (0.50) ALDH1A1KMT2APOLBRECQLALOX15
SCHEMBL28555018 0.82 CYP19A1 (0.55) ALDH1A1KMT2AMEN1MAPTHPGD
SCHEMBL17938760 0.81 MAPT (0.56) ALDH1A1KMT2APOLBRECQLCYP1A1
SCHEMBL705946 0.81 CYP19A1 (0.52) ALDH1A1KMT2APOLBRECQLMEN1
SCHEMBL5847123 0.79 ESR2 (0.43) ALDH1A1KMT2AALOX15ALOX12MEN1
SCHEMBL2071190 0.77 CA2 (0.45) ALDH1A1KMT2APOLBRECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114276966-A Astragalus membranaceus endophytic bacterium capable of producing isoflavone components and application thereof 黑龙江龙九堂药业有限公司 2022-04-05 CN disclosed
US-7906660-B2 Production of isoflavone derivatives NOVOGEN RESEARCH PTY LTD (AU) 2011-03-15 US disclosed
US-20060217564-A1 Production of isoflavone derivatives NOVOGEN RESEARCH PTY LTD. 2006-09-28 US disclosed
US-20050143588-A1 Production of isoflavone derivatives NOVOGEN RESEARCH PTY LTD. 2005-06-30 US disclosed
EP-1153020-A4 PRODUCTION OF ISOFLAVONE DERIVATIVES NOVOGEN RES PTY LTD (AU) 2002-08-21 EP disclosed
EP-1153020-A1 PRODUCTION OF ISOFLAVONE DERIVATIVES Novogen Research Pty. Ltd. (AU) 2001-11-14 EP disclosed
WO-2000049009-A1 PRODUCTION OF ISOFLAVONE DERIVATIVES NOVOGEN RESEARCH PTY. LTD. (AU) 2000-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217564-A1 Production of isoflavone derivatives CYP51A1, EGLN2, EGLN3 ALDH1A1 2979/4885KMT2A 2984/4885POLB 3777/4885
US-20050143588-A1 Production of isoflavone derivatives CYP51A1, EGLN2, EGLN3 ALDH1A1 2979/4885KMT2A 2984/4885POLB 3777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.